Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study

Table 1

Baseline (Day 1) demographic and clinical profile.

Parameters	IVIG + SoC group		Standard of care (SoC)		value
Number	33		26
Age (years)
Mean	56.94		59.73		0.1770
SD	8.69		6.44
Range	33–73		48–72
Gender
Male	22	66.67%	13	50%	0.1729
Female	11	33.33%	13	50%
Comorbidity profile
Hypertension	25	75.76%	21	81%	0.6079
T2 diabetes mellitus	18	54.55%	16	62%	0.5425
Obesity	4	12.12%	1	4%	0.2292
Bronchial asthma	1	3.03%	1	4%	0.8409
Chronic obstructive pulmonary disease	1	3.03%	1	4%	0.8409
Hypothyroidism	5	15.15%	4	15%	0.9045
Coronary artery disease	6	18.18%	5	19%	0.8113
Dilated cardiomyopathy	1	3.03%	0	0%	0.3748
Old pulmonary tuberculosis	4	12.12%	2	8%	0.6084
Baseline vital parameters (day 1)
Systolic BP (mm·Hg)	128.52 ± 17.21		128.88 ± 17.05		0.9185
Diastolic BP (mm·Hg)	78.52 ± 10.37		77.00 ± 9.31		0.7839
Pulse rate (beats/min)	93.42 ± 10.47		103.12 ± 16.43		0.0078
Respiratory rate (rate/min)	25.33 ± 3.89		24.92 ± 2.06		0.6033
SPO2 (on O2 support)	94.48 ± 3.79		91.65 ± 3.25		0.0037
Random blood sugar (mg/dL)	252.69 ± 97.43		270.64 ± 99.69		0.5317
Clinical severity
Moderate	6	18.18%	6	23%	0.6505
Severe	27	81.82%	20	77%
NEWS2 at admission (Day 1)
Mean	6.67		6.92		0.3907
SD	1.08		1.13
Range	4–8		3–9
CTSS score (Day 1)
Mean	21.67		21.23		0.5141
SD	2.25		2.90
Range	17–25		13–25

Bold values denote significant P-values (≤0.05).